Pulmonary hypertension (PH) comprises a heterogeneous group of disorders characterized by elevated pressure in the pulmonary arteries. Despite advances in awareness, utilization of non-invasive screening with echocardiography, increasing number of targeted therapies, and evolving clinical guidelines emphasizing referral to PH specialty centers, barriers to timely diagnosis and treatment persist.
Pulmonary arterial hypertension (PAH) is a progressive vasculopathy leading to right-sided heart failure. We have shown previously that the (NOD-like-receptor-3) NLRP3 inflammasome is activated in end-stage disease of the monocrotaline and aortocaval shunt (MCT/ACS) neointimal PAH rat model.
Whether hypoxia during popular high-altitude travel negatively affects cerebral oxygenation in vulnerable patients with pulmonary vascular disease (PVD) is unknown. We studied overnight cerebral tissue oxygen saturation (CTO) and desaturation index (cODI) in PVD-patients at 2500 m and effects of supplemental oxygen therapy (SOT).
Originally named T-cell-originated Lymphokine-activated killer protein kinase (TOPK), PDZ-Binding Kinase (PBK) is a serine/threonine kinase that is a member of the family of mitogen-activated protein kinases (MAPKKs), which is overexpressed in lung cancer and interstitial pulmonary fibrosis (IPF).
In 567 PH-COPD patients from the PVRI GoDeep Meta-Registry, ACE inhibitor use was associated with improved survival only in severe PH (PVR > 5 WU), supporting prospective trials targeting this high-risk subgroup.
The authors of “The Pulmonary Hypertension Global Patient Survey: Physical and Psychosocial Impacts on Health-Related Quality of Life,” along with the participants who bravely shared their experiences, are to be commended for this important contribution to the field.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct and potentially curable form of pulmonary hypertension; however, a substantial proportion of patients remain inoperable or experience persistent or recurrent disease. Pharmacological therapies targeting the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) pathway have emerged as promising treatment options.
Previous studies have shown that red blood cell distribution width (RDW) is an independent risk factor for the prognosis of pulmonary arterial hypertension (PAH) and is also associated with cardiovascular events in patients with congenital heart disease (CHD). However, its role in patients with CHD-associated pulmonary hypertension (PAH-CHD) has not been reported.
Pulmonary hypertension (PH) is a condition characterized by elevated mean pulmonary arterial pressure confirmed by right heart catheterization. PH involves both structural and functional changes in the pulmonary vascular bed.
Diagnosing pulmonary hypertension (PH) requires invasive right heart catheterization (RHC). However, mean pulmonary artery pressure (mPAP) can be non-invasively estimated using 4D analysis of cardiovascular magnetic resonance (CMR) flow imaging to assess the duration of pathological vortex flow (Tvortex) in the main pulmonary artery (MPA).
